Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Quest Diagnostics, Abbott, Enzo Biochem, Oligo Factory

NEW YORK – Quest Diagnostics said this week that it has completed its previously announced acquisition of PathAI Diagnostics from PathAI. Under the terms of the deal, which was originally announced in May, Quest acquired select assets of PathAI's anatomic and digital pathology lab services business PathAI Diagnostics. It also licensed PathAI's AISight digital pathology management system to support pathology labs and customer sites in the US and became a preferred provider for PathAI's biopharmaceutical clinical laboratory services. 

Enzo Biochem reported this week that its fiscal third-quarter revenues rose 7 percent to $8.0 million compared to $7.4 million in the year-ago quarter. For the quarter ended April 30, the firm reported a net loss of $3.0 million compared to a net loss of $15.2 million a year earlier. It ended the quarter with $57.2 million in cash and cash equivalents. 

Abbott this week announced that its board of directors has approved a quarterly dividend of $.55 per share, payable Aug. 15 to shareholders of record on July 15.

Oligo Factory said this week that it has received ISO 13485:2016 quality management systems certification for its facility in Holliston, Massachusetts. The firm said that the certification will extend its ability to manufacture and supply custom raw materials including primers, probes, and other nucleotides that are used in diagnostic assays. The ISO 13485:2016 standard relates to the ability to provide medical devices and related services while consistently meeting the requirements of customers and regulatory bodies. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.